## NBIX: Neurocrine Biosciences, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.27 indicates fundamental undervaluation.

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($143.98)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Neurocrine Biosciences (NBIX): Revisiting Valuation After a Year of Double-Digit Shareholder Returns**
- Source: Simply Wall Street | 20251214T200856 | Bullish | Relevance: 100%
- Neurocrine Biosciences (NBIX) has delivered steady double-digit returns for shareholders this year, with its stock up 11% year-to-date and 21% over the past year. Despite a perceived 38% undervaluation based on future growth, its current P/E ratio of 35.6x suggests investors are already paying a premium. The company's valuation hinges on strong future earnings and successful execution of clinical trials.

**2. How Neurocrine Biosciences Inc. (NBIX) Affects Rotational Strategy Timing**
- Source: Stock Traders Daily | 20251210T230400 | Bullish | Relevance: 100%
- Neurocrine Biosciences Inc. (NBIX) shows strong sentiment across all horizons, supporting an overweight bias. The article provides institutional trading strategies, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis, all generated by AI models. It highlights key findings like an exceptional short setup targeting 10.9% downside versus 0.3% risk.

**3. Thrivent Financial for Lutherans Cuts Stock Position in Neurocrine Biosciences, Inc. $NBIX**
- Source: MarketBeat | 20251214T100856 | Somewhat-Bullish | Relevance: 100%
- Thrivent Financial for Lutherans reduced its stake in Neurocrine Biosciences, Inc. by 10.4% in the second quarter, selling 91,516 shares and now holding 787,299 shares valued at approximately $98.96 million. Despite this reduction, Neurocrine Biosciences reported a strong quarter, exceeding analyst expectations for EPS and revenue, and institutional investors collectively own 92.59% of the stock. Analysts currently maintain a "Moderate Buy" consensus rating with an average target price of $173.33 for NBIX.

**4. Boone Capital Management LLC Makes New Investment in Neurocrine Biosciences, Inc. $NBIX**
- Source: MarketBeat | 20251213T093056 | Bullish | Relevance: 100%
- Boone Capital Management LLC has acquired a new stake of 180,338 shares in Neurocrine Biosciences Inc. (NBIX), valued at approximately $22.7 million, making it their sixth-largest holding. This comes as insider ownership has decreased to 4.8% due to recent sales, while institutional investors hold 92.59% of the stock. Neurocrine Biosciences recently surpassed Q3 earnings estimates with robust revenue growth, leading analysts to maintain a "Moderate Buy" rating with an average target price of $173.33.

**5. Neurocrine Biosciences, Inc. $NBIX is Braidwell LP's 3rd Largest Position**
- Source: MarketBeat | 20251213T092856 | Somewhat-Bullish | Relevance: 100%
- Braidwell LP recently decreased its stake in Neurocrine Biosciences (NASDAQ:NBIX) by 2.6%, yet the stock still constitutes its third-largest holding, representing 5.0% of its investment portfolio. Other institutional investors have also adjusted their positions, with several increasing their holdings in the first and second quarters. Insider selling activity has also been noted, with Darin Lippoldt and George J. Morrow collectively selling a significant number of shares recently.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Mizuho | $175 | $146 | +20% |
| 2025-12-11 | Stifel | $188 | $183 | +3% |
| 2025-12-08 | RBC Capital | $180 | $160 | +12% |
| 2025-12-05 | TD Cowen | $200 | $175 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Mizuho | main | Neutral |
| 2025-12-11 | Stifel | main | Buy |
| 2025-12-08 | RBC Capital | main | Outperform |
| 2025-12-05 | TD Cowen | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 4 ($1.77M) |
| Sells | 4 ($3.24M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 12.7% (-1.9%)
- Vanguard Group Inc: 9.7% (-1.0%)
- JPMORGAN CHASE & CO: 9.5% (+122.0%)
- Dodge & Cox Inc.: 5.6% (-0.2%)
- State Street Corpora: 4.4% (-2.7%)

### Key Risks

1. Insider selling cluster: $3.2M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +12%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.27 indicates undervaluation relative to growth. Forward P/E 16.7x attractive for 32% earnings growth. Quality metrics strong (margin 16%). Balance sheet: strong liquidity (3.4x), low leverage (D/E 0.42). Analyst sentiment positive (4 raises, avg +12%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $15.2B |
| Beta | 0.27 |
| 52W Range | $84.23 - $160.18 |
| Short Interest | 5.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.27 |
| Forward P/E | 16.7 |
| Current P/E | 22.1 |
| YoY Growth | 32.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 weakening modestly (-0.8% over 5 days). Below STRENGTH zone by 1.5pp (needs >4.0% for momentum thesis). MRS_5 at 0.2% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58. OFD pattern: -MLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.47% (CS: 58) | Neutral |
| RSI_14 | 57.7 | Neutral |
| MACD Histogram | 0.36 | Bullish |
| vs SMA20 | 1.028x | Above |
| vs SMA50 | 1.053x | Above |
| vs SMA200 | 1.185x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $152.80
- **Stop Loss:** $143.98 (5.8% risk)
- **Target:** $170.44 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 113
- **Position Value:** $17,266.40
- **Portfolio %:** 17.27%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-05 (Est: $2.41)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.07 | $2.17 | +4.9% |
| 2025Q2 | $1.50 | $1.65 | +9.6% |
| 2025Q1 | $1.09 | $0.70 | -36.0% |
| 2024Q4 | $1.93 | $1.69 | -12.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*